The legacy of Sildenafil offers a complicated case study for investors eyeing pharma. While first sales were remarkable, recent patent expiry and the emergence of cheaper versions have considerably impacted revenues. https://mariahuctd112133.dsiblogger.com/74104663/sildenafil-and-the-pharmaceutical-industry-a-risky-investment